Cyclin‐dependent kinase 4/6 inhibitors (CDK4/6i) have revolutionised the management of hormone receptor‐positive (HR+), HER2‐negative (HER2‒) advanced breast cancer (ABC).1, 2. This evidence concerns the gene ERBB2 and breast cancer.